It has been brought to the publisher\'s attention, that there was an error in Table 1 of the above article, published in *TH Open* , Volume 3, Number 3, 2019, pages e309--e315 (DOI: 10.1055/s-0039-1696659 ). In the SELECT-D study, it should state " *N*  = 406" instead of " *N*  = 203".

The correct table appears below.

###### Protocol design of randomized control trials on anticoagulants for the treatment of cancer-associated thrombosis

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study (year)               Study drug/comparator    Patients                                                                    Methods/statistics   Primary endpoint                                                                     Secondary endpoints        Duration (mo)
  -------------------------- ------------------------ --------------------------------------------------------------------------- -------------------- ------------------------------------------------------------------------------------ -------------------------- ---------------
  ONCENOX ^39^\              Enoxaparin/warfarin      Active cancer, acute symptomatic VTE                                        Pilot feasibility    VTE recurrence                                                                       Major and minor bleeding   6
  *N*  = 122 (2006)                                                                                                                                                                                                                                                    

  CANTHANOX ^25^\            Enoxaparin/warfarin      Active or treated cancer, PE, and/or DVT                                    S                    Composite of major bleeding or recurrent VTE                                         Recurrent VTE\             3
  *N*  = 146 (2002)                                                                                                                                                                                                                         Major bleeding             

  CLOT ^26^\                 Dalteparin/warfarin      Active cancers, acute proximal symptomatic DVT or PE                        Phase III/S          Symptomatic recurrence of DVT, PE, or both                                           Major bleeding\            6
  *N*  = 672 (2003)                                                                                                                                                                                                                         Any bleeding               

  LITE CANCER ^27^\          Tinzaparin/warfarin      Cancer, acute proximal DVT                                                  Phase III/S          Recurrent VTE or death                                                               Major and minor bleeding   3
  *N*  = 200 (2006)                                                                                                                                                                                                                                                    

  CATCH ^22^\                Tinzaparin/warfarin      Active cancers, acute proximal symptomatic DVT or PE                        Phase III/S          VTE recurrence: proximal DVT, PE either symptomatic or incidental                    Major bleeding\            6
  *N*  = 900 (2015)                                                                                                                                                                                                                         CRNMB                      

  SELECT-D ^23^\             Rivaroxaban/dalteparin   All active cancers, proximal DVT, PE, incidental PE                         Pilot                VTE recurrence: proximal DVT, PE either symptomatic or incidental, and other sites   Major bleeding\            6
  *N*  = 406 (2018)                                                                                                                                                                                                                         CRNMB                      

  HOKUSAI-VTE Cancer ^21^\   Edoxaban/dalteparin      Active or history of cancer, acute symptomatic or incidental VTE            Phase III/NI         Composite of VTE recurrence (symptomatic or incidental) or major bleeding            VTE recurrence\            12
  *N*  = 1,046 (2018)                                                                                                                                                                                                                       Major bleeding\            
                                                                                                                                                                                                                                            CRNMB                      

  CARAVAGGIO ^35^\           Apixaban/dalteparin      Active or history of cancer, symptomatic or incidental proximal DVT or PE   Phase III/NI         Symptomatic or incidental VTE recurrence                                             Major bleeding             6
  *N*  = 1,168 (2019)                                                                                                                                                                                                                                                  
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: CRNMB, clinically relevant nonmajor bleeding; DVT, deep-vein thrombosis; NI, noninferiority trial; PE, pulmonary embolism; S, superiority trial; VTE, venous thromboembolism.
